Tags: Life Sciences
Belgian Constitutional Court annuls new export prohibition for full-line wholesalers but new legislative proposals are already put forward
On 17 October 2019, the Belgian Constitutional Court annulled the export prohibition for wholesaler-distributors, which was introduced by Article 3, 2° of the Act concerning the unavailability of medicinal products of 7 April 2019.
Incentives and public procurement in the healthcare sector: be careful what you wish for!
Since the European Court of Justice’s ruling C-300/07 of 11 June 2009, hospitals and other health institutions must abide by public procurement law to the extent that they are at least 50% financed directly by public authorities or indirectly by public insurance schemes.
Towards a harmonised employee status by levelling up… Janssen Pharmaceutica sets an example
Very recently, a major player in the pharmaceutical sector, Janssen Pharmaceutica, has entered into a company CBA with the social partners that provides for full harmonisation between its blue-collar and white-collar employees, by abolishing the blue-collar worker status for all its workers from 1 October 2019.
New research exemption under Belgian patent law?
On 19 December 2017, the legislative package on the implementation of the UPC was approved by Belgian Parliament.
New rules to deal with the unavailability of medicinal products in Belgium
An Act of 7 April 2019 has introduced new measures in Belgium to deal with the unavailability of medicinal products on the Belgian market.
Companies beware! New prohibition in Belgium on the abuse of economic dependence
On 21 March 2019, the Federal Belgian Parliament adopted an Act amending the Code of Economic Law regarding abuses of economic dependence, prohibited terms and unfair market practices in B2B relationships.
Clinical Trials and the GDPR: do I really need the participant’s consent?
On 23 January 2019, the European Data Protection Board issued its Opinion 3/2019 on the interplay between the General Data Protection Regulation and the Clinical Trials Regulation.
Important financial impact for equity incentives expected in the life sciences industry
In the life-sciences industry, many employees benefit from equity incentives granted by the parent company.
Drastic times call for ex parte interim measures
In Belgium, a preliminary injunction is rarely granted on an ex parte basis. Adversarial debates are considered as a cornerstone of legal proceedings, and one is entitled to deviate from this principle only in the case of so-called ‘absolute necessity’.
Anti-tampering devices : fading boundaries of parallel trade?
On 9 February 2019, a legislative package aimed at fighting medicines falsifications will enter into force across the EU.